Rivaroxaban and Aspirin in Peripheral Artery Disease L Revascularization

Circulation

142, 2219-2230

DOI: 10.1161/circulationaha.120.050465

Citation Report

#	Article	IF	Citations
1	Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease. Heart International, 2021, 15, 14-19.	2.6	2
2	Are There Alternatives to Dual Antiplatelet Therapy After Stenting of Peripheral Arteries?. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 2021, 27, 22-27.	0.2	1
3	Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 11, 608247.	5.3	9
4	The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization. JACC: Cardiovascular Interventions, 2021, 14, 796-802.	5.0	8
5	Considerations for Use of Direct Oral Anticoagulants in Arterial Disease. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12502.	3.3	3
6	Advances in Revascularization for Peripheral Artery Disease: Revascularization in PAD. Circulation Research, 2021, 128, 1885-1912.	15.7	228
7	Medical Management of Peripheral Arterial Disease: Deciphering the Intricacies of Therapeutic Options. CJC Open, 2021, 3, 936-949.	1.8	9
8	Antithrombotic Therapies in Aortic and Peripheral Arterial Diseases in 2021: A Consensus Document From the ESC Working Group on Aorta and Peripheral Vascular Diseases, the ESC Working Group on Thrombosis, and the ESC Working Group on Cardiovascular Pharmacotherapy. European Heart Journal, 2021, 42, 4013-4024.	14.7	135
9	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation, 2021, 144, 1104-1116.	24.6	48
10	Antithrombotic Treatment for Peripheral Arterial Occlusive Disease. Deutsches Ärzteblatt International, 2021, 118, 528-535.	3.5	7
11	Pharmacodynamic Profiles of Dual-Pathway Inhibition With or Without Clopidogrel Versus Dual Antiplatelet Therapy in Patients With Atherosclerotic Disease. Thrombosis and Haemostasis, 2022, 122, 1341-1351.	4.6	21
12	Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making. Canadian Journal of Cardiology, 2022, 38, 654-661.	3.8	7
13	When and How to Combine Antiplatelet and Anticoagulant Drugs?. Hamostaseologie, 2022, 42, 073-079.	1.5	24
14	Prevention of Arterial and Venous Thrombotic Events in Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD Trial: Dual Anticoagulant/Antiplatelet Regimen vs Antiplatelet Therapy Alone. Journal of Thrombosis and Haemostasis, 2022, 20, 1193-1205.	5.0	15
15	Flow Cytometry Based Platelet Reactivity Testing to Predict the Occurrence of Per-Operative Solid Microemboli During Carotid Endarterectomy. European Journal of Vascular and Endovascular Surgery, 2022, 63, 800-806.	3.2	3
16	Antithrombotic Treatment in Lower Extremity Peripheral Arterial Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 773214.	3.2	9
17	Management of Chronic Peripheral Artery Disease Patients With Indication for Endovascular Revascularization. Vasa - European Journal of Vascular Medicine, 2022, 51, 121-137.	2.7	27
18	Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3235.	1.4	134

#	Article	IF	Citations
19	Optimal Conduit Choice for Open Lower Extremity Bypass in Chronic Limb-Threatening Ischemia. Seminars in Vascular Surgery, 2022, 35, 172-179.	2.8	14
20	Efficacy and Safety of Rivaroxaban Versus Placebo After Lower Extremity Bypass Surgery: A Post Hoc Analysis of a "CASPAR Like" Outcome From VOYAGER PAD. Clinical Cardiology, 2022, 45, 1143-1146.	3.1	11
21	Antithrombotic Therapy in Peripheral Arterial Disease. Frontiers in Cardiovascular Medicine, 2022, 9, 927645.	3.2	10
22	Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. Journal of the Society for Cardiovascular Angiography & Interventions, 2022, 1, 100513.	2.3	25
23	Serum High Mobility Group Box-1 Levels Associated With Cardiovascular Events After Lower Extremity Revascularization: A Prospective Study of a Diabetic Population. Cardiovascular Diabetology, 2022, 21, 1-14.	15.7	11
24	Antithrombotic Therapy Following Revascularization for Chronic Limb-Threatening Ischaemia: A European Survey From the ESC Working Group on Aorta and Peripheral Vascular Diseases. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 201-207.	5.0	15
25	Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions. Seminars in Interventional Radiology, 2022, 39, 364-372.	1.1	2
26	Antithrombotische Therapie bei pAVK und Aortenerkrankungen. Aktuelle Kardiologie, 2022, 11, 560-564.	0.0	5
27	Use of Direct-Acting Oral Anticoagulants Associated With Improved Survival and Bypass Graft Patency Compared With Warfarin After Infrageniculate Bypass. Journal of Vascular Surgery, 2023, 77, 1453-1461.	3.4	12
28	Rivaroxaban in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Bypass Surgery With Venous and Prosthetic Conduits. Journal of Vascular Surgery, 2023, 77, 1107-1118.e2.	3.4	21
29	Dual Pathway Inhibition in Patients With Atherosclerotic Disease: Pharmacodynamic Considerations and Clinical Implications. Expert Review of Clinical Pharmacology, 2023, 16, 27-38.	3.6	18
30	Secondary Prevention of Antithrombotic Therapy in Patients With Stable Cardiovascular Disease at High Ischemic Risk: A Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Cardiovascular Medicine, 2023, 9, 1040473.	3.2	4
31	Patient Characteristics in the Recording Courses of Vascular Diseases (Reccord) Registry: Comparison With the Voyager Pad Endovascular Cohort. Journal of Cardiovascular Development and Disease, 2023, 10, 115.	2.9	2
32	Evidenzbasierte antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit (PAVK). Gefasschirurgie, 2023, 28, 208-215.	0.4	2
33	Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. European Journal of Vascular and Endovascular Surgery, 2023, 65, 627-689.	3.2	194
34	Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. Journal of Cardiovascular Development and Disease, 2023, 10, 164.	2.9	21
35	Optimization of the Pharmacological Therapy in Patients With Poly-Vascular Disease: A Multidisciplinary Approach. World Journal of Cardiology, 2023, 15, 142-153.	2.5	8
36	Comprehensive Care of Lower-Extremity Wounds. Surgical Clinics of North America, 2023, 103, 745-765.	2.6	7

#	Article	IF	Citations
37	CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt. Journal of Epidemiology and Global Health, 2023, 13, 374-383.	4.4	5
38	Oral Factor Xa Inhibitor Underutilization Following Lower Extremity Peripheral Vascular Intervention. Journal of Vascular Surgery, 2023, 78, 498-505.e1.	3.4	8
39	Medical Management of Peripheral Artery Disease. Seminars in Interventional Radiology, 2023, 40, 119-128.	1.1	3
40	Focus on Prevention: Peripheral Arterial Disease and the Central Role of the Cardiologist. Journal of Clinical Medicine, 2023, 12, 4338.	3.8	7
41	Peripheral Arterial Disease and the Pharmacist's Role in Management. Journal of Clinical Pharmacy and Therapeutics, 2023, .	1.0	0
42	Trattamento endovascolare delle lesioni ateromatose del segmento femoropopliteo. EMC - Tecniche Chirurgiche Vascolare, 2023, 28, 1-12.	0.0	0
43	The Intersocietal IWGDF, ESVS, SVS Guidelines on Peripheral Artery Disease in People With Diabetes and a Foot Ulcer. Diabetes/Metabolism Research and Reviews, 2024, 40, e3686.	8.4	160
44	The Intersocietal IWGDF, ESVS, SVS Guidelines on Peripheral Artery Disease in People With Diabetes Mellitus and a Foot Ulcer. Journal of Vascular Surgery, 2023, 78, 1101-1131.	3.4	93
45	Editor's Choice – The Intersocietal IWGDF, ESVS, SVS Guidelines on Peripheral Artery Disease in People With Diabetes Mellitus and a Foot Ulcer. European Journal of Vascular and Endovascular Surgery, 2023, 66, 454-483.	3.2	74
46	Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD. Circulation, 2023, 148, 1919-1928.	24.6	22
47	Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication☆. European Journal of Vascular and Endovascular Surgery, 2024, 67, 9-96.	3.2	532
48	Catheter Directed Thrombolysis in Acute Limb Ischemia Patients. A Single Center's Experience. Wiadomości Lekarskie, 2023, 76, 2156-2160.	0.5	2
49	Direct Oral Anticoagulants Over Warfarin at Discharge Associated With Improved Survival and Patency in Infra-Geniculate Bypasses With Prosthetic Conduits. Journal of Vascular Surgery, 2024, 79, 609-622.e2.	3.4	7
50	Platelet Function Testing and Clinical Outcomes in Peripheral Arterial Disease: Systematic Review and Narrative Synthesis. Journal of Vascular Surgery, 2024, 0, 269-278.	3.4	8
51	Intravascular Ultrasound Use in Peripheral Arterial and Deep Venous Interventions: Multidisciplinary Expert Opinion From SCAI/AVF/AVLS/SIR/SVM/SVS. Journal of Vascular and Interventional Radiology, 2024, 35, 335-348.	2.2	24
52	Intravascular Ultrasound Use in Peripheral Arterial and Deep Venous Interventions: Multidisciplinary Expert Opinion From SCAI/AVF/AVLS/SIR/SVM/SVS. Journal of the Society for Cardiovascular Angiography & Interventions, 2024, 3, 101205.	2.3	19
53	Intravascular Ultrasound Use in Peripheral Arterial and Deep Venous Interventions: Multidisciplinary Expert Opinion From SCAI/AVF/AVLS/SIR/SVM/SVS. JVS-Vascular Insights: An Open Access Publication from the Society for Vascular Surgery, 2024, 0, 100033.	0.9	4
54	BEST-CLI International Collaborative: Planning a Better Future for Patients With Chronic Limb-Threatening Ischaemia Globally. British Journal of Surgery, 2024, .	3.9	11

#	Article	IF	Citations
55	Predictors of Major Adverse Lower Limb Events in Patients With Tissue Loss Secondary to Critical Limb-Threatening Ischemia. Cardiovascular Revascularization Medicine, 2024, 64, 34-41.	1.6	2
56	The Paradox of Direct-Acting Anticoagulants in Peripheral Arterial Disease in Spain. Angiologia, 2024, .	0.1	0
57	Clinical Practice Recommendations for Antithrombotic Management of Peripheral Artery Disease: An Indian Perspective. Indian Journal of Vascular and Endovascular Surgery, 2024, 11, 4.	0.3	2
58	Evaluation of Plasma Biomarkers for Causal Association With Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2024, 44, 1114-1123.	7.9	13
59	Rationale and Design of the Latin-American Registry of Peripheral Interventions: Insights From SOLACI Peripheral. Journal of the Society for Cardiovascular Angiography & Interventions, 2024, 0, 101931.	2.3	2
60	Dual-Pathway Inhibition With Low-Dose Aspirin and Rivaroxaban Versus Aspirin Monotherapy in Patients With Coronary Artery Disease and Peripheral Artery Disease: Systematic Literature Review and Meta-Analysis. European Cardiology Review, 2023, 19, e01.	2.4	15
61	Medical Therapy for Peripheral Artery Disease. Current Cardiology Reports, 2024, 26, 651-659.	4.5	13
62	Practice Patterns of Antiplatelet and Anticoagulant Therapy After Fenestrated/Branched Endovascular Aortic Repair. Journal of Vascular Surgery, 2024, 80, 968-978.e3.	3.4	12
63	Medical Therapy of PAD. , 2024, .		0
64	Perioperative Platelet Reactivity Over Time in Patients Undergoing Vascular Surgery: An Observational Pilot Study. PLoS ONE, 2024, 19, e0304800.	3.2	5
65	Antithrombotic Therapy in Patients Undergoing Peripheral Artery Interventions. Interventional Cardiology Clinics, 2024, 13, 553-559.	1.1	1
66	Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific Statement. Journal of the American College of Cardiology, 2024, 84, 936-952.	12.0	24
67	2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases: Developed by the Task Force on the Management of Peripheral Arterial and Aortic Diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM). European Heart Journal, 2024, 45, 3538-3700.	14.7	1,197
68	Maladie artérielle périphérique. , 2024, .		0
69	Brazilian Society of Angiology and Vascular Surgery Guidelines on Peripheral Artery Disease. Jornal Vascular Brasileiro, 2024, 23, e20230059.	1.0	11
70	Antithrombotic Therapy in High Bleeding Risk, Part II: Noncardiac Percutaneous Interventions. JACC: Cardiovascular Interventions, 2024, 17, 2325-2336.	5.0	16
71	Rivaroxaban Plus Aspirin After Lower–Extremity Revascularization. Expert Review of Hematology, 2024, 17, 877-884.	2.7	1
72	Impact of Dual Antithrombotic Therapy With Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes. Medical Science Monitor, 2024, 30, e945457.	2.4	1

#	Article	IF	Citations
73	Rivaroxaban to Reduce the Risk of Major Cardiovascular Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease: A Narrative Review. Expert Opinion on Drug Safety, 2025, 24, 261-271.	3.2	7
74	Association Between Guideline-Directed Medical Therapy and Reintervention Risk Following Peripheral Vascular Interventions in Patients With Peripheral Artery Disease. Vascular Medicine, 2025, 30, 293-301.	2.3	5
75	Early Risk of Major Adverse Limb Events Following Lower Extremity Revascularization in the VOYAGER-PAD Trial. JACC: Cardiovascular Interventions, 2025, 18, 1211-1213.	5.0	0
76	Short-Term Effects of Rivaroxaban Combined With Aspirin in the Treatment of Lower Limb Arterial Atherosclerosis Occlusion With Stent Placement: A Retrospective Study. Medicine (United States), 2025, 104, e42147.	2.1	0
77	Intravascular Imaging for Peripheral Artery Disease and Endovascular Intervention of the Lower Extremities. Current Cardiovascular Imaging Reports, 2025, 18, 6.	0.7	3
78	Society for Vascular Surgery Clinical Practice Guideline on the Management of Intermittent Claudication: Focused Update. Journal of Vascular Surgery, 2025, 82, 303-326.e11.	3.4	28
79	Antithrombotic Treatment Following Revascularization for Chronic Limb-Threatening Ischaemia: A Scientific Statement of the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal, 2025, 46, 2742-2759.	14.7	6
80	Warfarin and DOAC Impact on Cardiovascular and Limb Outcomes in Patients With Peripheral Arterial Disease. Vasa - European Journal of Vascular Medicine, 2025, 54, 273-279.	2.7	2
81	Aspirin Plus Rivaroxaban vs Aspirin Alone: Improvement of Claudication, Limb Pain and Ankle-Brachial Index in Diabetic Peripheral Arterial Disease (PAD) Before Revascularization: A Clinical Randomized Trial. International Cardiovascular Research Journal, 2025, 19, e154736.	0.4	1
82	Antithrombotische Therapie Bei Polyvaskulärer Atherosklerose. Deutsche Medizinische Wochenschrift, 2025, 150, 741-746.	0.3	0
83	Analysis of the Outcomes of Catheter-Directed Thrombolysis in Patients With Lower Limb Arterial Thrombosis Involving Outflow Arteries. Клінічна та профілактична медицина, 2025, .	0.4	1
84	Oral Anticoagulant Management for Peripheral Vascular Disease. Advances in Surgery, 2025, 59, 161-199.	2.1	0
85	Peripheral Artery Disease and Antithrombotic Management: A Global Perspective on Efficacy, Safety, and Access. Cardiology in Review, 2025, .	1.7	1
86	Novel Interventions to Improve Adherence to Guideline-Directed Medical Therapy in Claudicants. Journal of Clinical Medicine, 2025, 14, 5309.	3.8	0
87	Antithrombotic Therapy for Lower Limb Peripheral Arterial Disease: A Deep Dive Into Guideline Quality and Recommendation Diversity. Thrombosis Research, 2025, 253, 109414.	2.9	1
88	Chirurgia a cielo aperto ed endovascolare del treppiede femorale. EMC - Tecniche Chirurgiche Vascolare, 2025, 30, 1-11.	0.0	0
89	Comparative Analysis of the Treatment of Patients With Lower Limb Artery Thrombosis and Outflow Artery Injury Using Recombinant Tissue Plasminogen Activator as a Thrombolytic Agent. Ukrainian Journal of Cardiovascular Surgery, 2025, 33, 81-87.	0.2	0
90	Dual Versus Single Antiplatelet Therapy After Lower Extremity Revascularization in Peripheral Artery Disease: A Systematic Review and Meta-Analysis. World Journal of Cardiology, 2025, 17, 111941.	2.5	2

#	Article	IF	Citations
91	Risk Factors for Claudication and Management to Modify Them. , 2025, .		0
92	Nanostructured Delivery Systems for Curcumin: Improving Bioavailability and Plaque-Targeting Efficacy in Atherosclerosis. Pharmaceutics, 2025, 17, 1465.	7.5	6
93	Антитромботическая терапия после реконструктивных операций на артериях конечностей. Обзор литературы. Непрерывное медицинское образование и наука, 2025, 20, 3-8.	0.0	0
94	Optimal Antithrombotic Regimens Across Atherosclerotic Vascular Beds: Toward Mechanism and Risk-Oriented Strategies. Journal of Clinical Medicine, 2026, 15, 2325.	3.8	3
95	Timing of Restenosis and Reocclusion Following Endovascular Therapy for Femoropopliteal Lesions. Cureus, 2026, 18, e107342.	1.3	0
96	Antithrombotic Therapy After Lower Limb EndoVascular Interventions: Are We Overtreating or Undertreating? - A Narrative Review. Cardiology in Review, 2026, .	1.7	0
97	Efficacy and Safety of Rivaroxaban in Patients With Peripheral Artery Disease: A GRADE-Assessed Systematic Review and Meta-Analysis. Annals of Vascular Surgery, 2026, 132, 662-674.	1.8	0
98	Peripheral Artery Disease: Advances in Medical Therapy. European Heart Journal, 2026, .	14.7	2
99	CIRSE Standards of Practice for the Endovascular Management of Acute Lower Limb Ischaemia. CardioVascular and Interventional Radiology, 2026, .	2.3	0
100	PAD as a Marker of Systemic Atherosclerosis: A Comprehensive Review of Residual Risk and Contemporary Strategies for MACE and MALE Reduction. Medicina (Lithuania), 2026, 62, 1905.	3.3	0
101	Polyvascular Atherosclerotic Disease Across Contemporary ESC Guidelines: Key Updates, Clinical Gaps, and Future Perspectives. Medicina (Lithuania), 2026, 62, 2047.	3.3	0